Ultragenyx Expects 20 percent Revenue Growth in 2024 and Profitability in 2026

Posted on LinkedIn by CNBC Overtime, “The rare disease biotech company Ultragenyx says it expects 20 percent revenue growth in 2024 and profitability in 2026.

Ultragenyx founder and CEO Dr. Emil Kakkis joined us from the JPMorgan Chase & Co. Health Care conference to discuss the regulatory and approval challenges in developing and bringing a blockbuster drug for rare diseases to market, new therapies coming down the pipeline, and what the biotech company is doing to accelerate ‘good science into great medicine.'”